Skip to main content

Table 1 Main baseline characteristics of the study population (n = 202) by liver fibrosis stage using transient elastography (TE)

From: Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers

Variable All patients Patients with
TE < 7.1 kPa
Patients with
TE ≥ 7.1 kPa
p-value
Mean age, years 47 ± 9 46.7 ± 9 49 ± 9 0.20
Male gender, n (%) 159 (79) 135 (80) 24 (73) 0.36
Caucasian Ethnicity, n (%) 190 (94) 157 (93) 33 (100) 0.87
CD4 count (cells/μl), mean ± SD 591 ± 254 591 ± 240 589 ± 323 0.57
Estimated duration of HIV infection in years, mean ± SD 13 ± 7 13 ± 7 15 ± 6 0.70
HBV co-infection, n (%) 18 (9) 13 (8) 5 (15) 0.18
HCV co-infection, n (%) 35 (17) 16 (10) 19 (58) < 0.0001
Chronic ALT elevation, n (%) 55 (27) 38 (23) 17 (52) 0.001
Chronic AST elevation, n (%) 38 (19) 19 (11) 19 (58) < 0.0001
Chronic γ-GT elevation, n (%) 98 (49) 73 (43) 25 (76) 0.001
Exposure to cART, n (%) 179 (89) 148 (88) 31 (94) 0.38
   months on NRTI     
   mean ± SD 188 ± 135 186 ± 138 199 ± 124 0.60
   months on NNRTI     
   mean ± SD 36 ± 44 38 ± 47 32 ± 34 0.68
   months on PI     
   mean ± SD 90 ± 114 83 ± 108 131 ± 135 0.72
   Months on d-drugs     
   mean ± SD 32 ± 48 27 ± 44 55 ± 64 0.006
BMI (kg/m2), mean ± SD 23.4 ± 3.0 23.2 ± 2.8 24.7 ± 3.7 0.06
HOMA-IR, mean ± SD 2.4 ± 2.3 2.1 ± 1.8 3.8 ± 4.0 0.006
Total serum cholesterol (mg/dl),     
mean ± SD 203 ± 45 209 ± 45 176 ± 34 < 0.0001
  1. P-values are given for differences between patients with TE values < 7.1 kPa (n = 169) vs. ≥ 7.1 kPa (n = 33)
  2. cART, combination antiretroviral therapy; NRTI nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; d-drugs, stavudine, didanosine, or zalcitabine